1. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2009. CA Cancer J Clin 59:225-249, 2009.
2. Carlson KJ, Skates SJ, Singer DE: Screening for ovarian cancer. Ann Intern Med 121:124-132, 1994.
3. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003.
4. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003.
5. Clark R: Principles of cancer screening. Semin Roentgenol 38:718, 2003.
6. Eddy DM (ed): Common Screening Tests. Philadelphia: American College of Physicians, 1991.
7. Hulka BS: Cancer screening. Degrees of proof and practical application. Cancer 62(8 Suppl):1776-1780, 1988.
8. Chu CS, Rubin SC: Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 20:307-320, 2006.
9. Shridhar V, Lee J, Pandita A, et al: Genetic analysis of early-versus late-stage ovarian tumors. Cancer Res 61:5895-5904, 2001.
10. Mok CH, Tsao SW, Knapp RC, et al: Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 52:5119-5122, 1992.
11. Jacobs IJ, Kohler MF, Wiseman RW, et al: Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 84:1793-1798, 1992.
12. Skates SJ, Jacobs JI, MacDonald N, et al: Estimated duration of pre-clinical ovarian cancer from longitudinal CA 125 levels. Proc Am Assoc Cancer Res 43, 1999.
13. Hogg R, Friedlander M: Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 22:1315-1327, 2004.
14. van Nagell JR, Jr, DePriest PD, Reedy MB, et al: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 77:350-356, 2000.
15. van Nagell JR, Jr, DePriest PD, Ueland FR, et al: Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 109:1887-1896, 2007.
16. Jacobs I, Bast RC, Jr: The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4:1-12, 1989.
17. Bast RC, Jr, Klug TL, St John E, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887, 1983.
18. Jacobs IJ, Skates S, Davies AP, et al: Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. Br Med J 313:1355-1358, 1996.
19. Einhorn N, Sjovall K, Knapp RC, et al: Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 80:14-18, 1992.
20. Jacobs IJ, Skates SJ, MacDonald N, et al: Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353:12071210, 1999.
21. Westhoff C: Current status of screening for ovarian cancer. Gynecol Oncol 55:S34-S37, 1994.
22. Buys SS, Partridge E, Greene MH, et al: Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193:1630-1639, 2005.
23. Skates SJ, Menon U, MacDonald N, et al: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 21(10 Suppl):206-210, 2003.
24. Menon U, Gentry-Maharaj A, Ryan A, et al: Recruitment to multicentre trials - lessons from UKCTOCS: descriptive study. Br Med J 337:2079a, 2008.
25. Menon U, Gentry-Maharaj A, Hellett R, et al: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10:308-309, 2009.
26. Bast RC, Jr, Skates S, Zhang Z, et al: Optimizing a two-stage strategy for early detection of ovarian cancer. NCI translates: NCI Translational Science Meeting 2008; 300, no. 292.
27. Woolas RP, Xu FJ, Jacobs IJ, et al: Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85:1748-1751, 1993.
28. Zhang Z, Yu Y, Xu F, et al: Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 107:526-231, 2007.
29. Skates SJ, Horick N, Yu Y, et al: Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 22:4059-4066, 2004.
30. Hellstrom I, Hellstrom KE: SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol 622:15-21, 2008.
31. Badgwell D, Lu Z, Cole L, et al: Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol 106:490-497, 2007.
32. Xu Y, Shen Z, Wiper DW, et al: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280:719-723, 1998.
33. Bast RC, Jr, Brewer M, Zou C, et al: Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 174:91-100, 2007.
34. Yousef GM, Diamandis EP: Expanded human tissue kallikrein family—a novel panel of cancer biomarkers. Tumour Biol 23:185-192, 2002.
35. Diamandis EP, Scorilas A, Fracchioli S, et al: Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 21:1035-1043, 2003.
36. Zhang H, Kong B, Qu X, et al: Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol Oncol 102:61-66, 2006.
37. Petricoin EF, Ardekani AM, Hitt BA, et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572577, 2002.
38. Fisher WG, Rosenblatt KP, Fishman DA, et al: A robust bio-marker discovery pipeline for high-performance mass spectrom-etry data. J Bioinform Comput Biol 5:1023-1045, 2007.
39. Baggerly KA, Morris JS, Edmonson SR, Coombes KR: Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 97:307-309, 2005.
40. Baggerly KA, Morris JS, Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20:777-785, 2004.
41. Clarke CH, Buckley JA, Fung ET: SELDI-TOF-MS proteomics of breast cancer. Clin Chem Lab Med 43:1314-1320, 2005.
42. Zhang Z, Bast RC, Jr, Yu Y, et al: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64(16):5882-5890, 2004.
43. Clarke CH, Fung ET, Yip C, et al: A panel of proteomic markers improves the sensitivity of CA125 for detecting Stage I epithelial ovarian cancer. Proc Am Soc Clin Oncol 26:303s, no. 5542, 2008.
44. Gorelik E, Landsittel DP, Marrangoni AM, et al: Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 14:981-987, 2005.
45. Visintin I, Feng Z, Longton G, et al: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14:1065-1072, 2008.
46. NCCN Clinical Practice Guidelines in Oncology: Genetic/ Familial High-Risk Assessment: Breast and Ovarian. Rockledge, PA: National Comprehensive Cancer Network, 2006.
47. Laframboise S, Nedelcu R, Murphy J, et al: Use of CA-125 and ultrasound in high-risk women. Int J Gynecol Cancer 12:86-91, 2002.
48. Liede A, Karlan BY, Baldwin RL, et al: Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 20:1570-1577, 2002.
49. Stirling D, Evans DG, Pichert G, et al: Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics system. J Clin Oncol 23:55885596, 2005.
50. Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M: CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 100:20-26, 2006.
51. Lu KH, Garber JE, Cramer DW, et al: Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18:2728-2732, 2000.
52. Colgan TJ, Murphy J, Cole DE, et al: Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25:1283-1289, 2001.
53. Powell CB, Kenley E, Chen LM, et al: Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127-132, 2005.
54. Leeper K, Garcia R, Swisher E, et al: Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 87:52-56, 2002.
55. Hensley ML, Robson ME, Kauff ND, et al: Pre- and postmeno-pausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecol Oncol 89:440-446, 2003.
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.